Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by TheRock07on Nov 12, 2016 1:52pm

123 Views

Post# 25453350

RE:The New Cipher

One final point which I had forgotten, Cipher is paying $5.8 million CAD per year on its senior debt.

By selling its US assets, that debt can be extinguished which will add another $0.20 per share to net earnings and would boost fair value to about $15.

That, of course, is what Cipher was trading at just before they acquired these US assets..

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal